Brian Lian founded publicly traded Viking Therapeutics to focus on metabolic diseases. With obesity drugs in development and ...

Novo Nordisk 's ( NVO +2.93%) shareholders must be happy to see 2025 finally come to a close. It was not a good year for the ...

Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including ...

The U.S. Food and Drug Administration has approved the first pill version of a GLP-1 drug for weight loss, a move that could significantly widen access to the treatment for ...

Until now, they've largely been injectable drugs - Ozempic, Wegovy, Mounjaro, Zepbound. They're all weekly shots. The Food and Drug Administration approved the Wegovy pill on December 22. It has the ...

The price of weight-loss drugs like Wegovy put them out of reach for most people with obesity, but new arrivals and expiring ...

Novo Nordisk has had a difficult year: a tumbling stock price resulting in the biggest leadership shakeup in the company's ...

With Serena Williams, Amy Schumer, Andy Cohen, Meghan Trainor and more stars giving the various weight loss medicines a shot, ...

Here's when you can get the FDA-approved, daily pill version of Novo Nordisk's wildly popular GLP-1 drug Wegovy.

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

U.S. regulators this week gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.